SearchPublisher and Institutes
You are here: Home :: Area NEM :: Medical science :: Human medicine
Paul R. J. Ames, Antonio Ciampa, Maurizio Margaglione, Giovanna Scenna, Luigi Iannaccone, Vincenzo Brancaccio
Bleeding and re-thrombosis in primary antiphospholipid syndrome on oral anticoagulation: An 8-year longitudinal comparison with mitral valve replacement and inherited thrombophilia
The aimof this studay was to compare bleeding and re-thrombosis in primary antiphospholipid syndrome (PAPS), mitral valve replacement (MVR) and inherited thrombophilia (IT) at different oral anticoagulation intensities. It entailed a prospective 8-year follow-up on 67 patients with PAPS,89 with IT and 24 with MVR. Anticardiolipin (aCL) antibodies detected by Elisa and lupus anticoagulant by clotting assays. At INR 23 minor bleeding rate was higher in MVR (33.3) than PAPS (10.9) and IT (4.2)(p<0.0001).At INR 34 minor bleeding rate was higher in PAPS (142) than IT (33.3) and MVR (5.8)(p<0.0001). At either INR major bleeding rate were not significantly different across the three groups, but in PAPS major and minor bleeding rates were superior at INR 34 than INR 23 (p=0.02 and p<0.0001). Re-thrombosis rate was higher in PAPS than IT at INR 23 (4.0 vs 0.35) (p=0.01) and at INR 34 (10.5 vs. nil). The hazard ratio for re-thrombosis between PAPS and IT was 13 (95% IC 1.6102.2, p=0.015). By regression analysis, baseline IgG aCL titre (>80 GPL) p=0.001) and male sex (p=0.03) independently predicted re-thrombosis. In conclusion, in PAPS, high intensity oral anticoagulation was not superior to conventional intensity in preventing re-thrombosis but was offset by greater bleeding rates. Male sex and elevated baseline IgG aCL predicted rethrombosis in PAPS that is 13-fold more re-thrombogenic than IT.
Thrombosis and Haemostasis, Schattauer
Print ISSN: 0340-6245
Volume: 93, 04/2005
Pages: 694 - 699